Sacituzumab Tirumotecan in an Advanced HR+/HER2-Breast Cancer Patient with Bone Marrow Metastasis-Induced Refractory Thrombocytopenia: A Case Report and Literature Review
https://t.co/rCms7cI0yw
Extrapulmonary small cell carcinoma treated with conventional or tumor-targeted topoisomerase I inhibition plus ATR blockade: Clinical outcomes and molecular correlates.
https://t.co/BrVm7Sbfoq
Development of payload-resistant human ovarian cancer cell lines to better understand antibody-drug conjugate sequencing and resistance mechanisms.
https://t.co/izg9VicX23
Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NCI10208).
https://t.co/wdqNKFNH9e
Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.
https://t.co/uakIhuwWBZ
A phase II study of trastuzumab emtansine (T-DM1) combined with ribociclib in patients with HER2-positive metastatic breast cancer (RibHER).
https://t.co/nF8CbOpU10
Real-world outcomes and tumor gene expression analysis of sacituzumab govitecan (SG)- and trastuzumab deruxtecan (T-DXd)-treated metastatic breast cancer (MBC).
https://t.co/OamZ5HJb1G
ADC opens door to PARPi combo. Dr. Elizabeth Lee @DanaFarberNews shared data in phase 1 study of T-Dxd & PARP-inhib in #HER2+ ovarian & endometrial cancers. This combo tx may avoid toxicities of PARP + chemo combos, due to #ADC specificity. #AACR26 Additnal studies planned.
Honored to present our teams research @SGO_org in Puerto Rico
1. Claudin-6, an ADC target, is expressed in 50% of ovarian cancers!! With little overlap with folate receptor and HER2
2. MIRV resistance mechanisms- possibly through JAK1 VEGFR2 and MAPK mutations- exploratory but we need more data to understand MIRV resistance
Incredibly grateful to my mentors Dr Konecny, @dradityabardia , Dr Slamon and many more!
Outcomes with subsequent therapies post-enfortumab vedotin/pembrolizumab (EVP) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
https://t.co/fOW8RDwEHE
Impact of prior immune checkpoint inhibitor (ICI) and interval from ICI exposure on outcomes with enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).
https://t.co/EEg28CU2nA
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study
https://t.co/MXCZNXqlZ6